# ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCG

> **NCT06800963** · PHASE1,PHASE2 · RECRUITING · sponsor: **ImmunityBio, Inc.** · enrollment: 40 (estimated)

## Conditions studied

- NMIBC

## Interventions

- **BIOLOGICAL:** Intravesical Recombinant Mycobacterium (rMBCG)

## Key facts

- **NCT ID:** NCT06800963
- **Lead sponsor:** ImmunityBio, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-15
- **Primary completion:** 2028-02
- **Final completion:** 2028-02
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06800963

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06800963, "ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCG". Retrieved via AI Analytics 2026-08-20 from https://api.ai-analytics.org/clinical/NCT06800963. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*